 Both anti-transglutaminase and anti-endomysial antibodies have high sensitivity to diagnose people with classic symptoms and complete villous atrophy, but they are only found in 30–89% of the cases with partial villous atrophy and in less than 50% of the people who have minor mucosal lesions (duodenal lymphocytosis) with normal villi.Tissue transglutaminase modifies gluten peptides into a form that may stimulate the immune system more effectively.These peptides are modified by tTG in two ways, deamidation or transamidation.